#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Mick Verhagen Email
Research associate . Synaffix BV
,
LocationPrimary Email
How to contact Mick Verhagen
Join and see Mick's contact info for free!Current Roles
Employees:
41Revenue:
$6.4MAbout
Synaffix BV is a Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability of ADC drugs compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) that enables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035. Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products using our proprietary technology. We anticipate first-in-human studies with ADCs prepared using Synaffix technology to be initiated by our partners in 2018. We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.Synaffix BV Address
null, null